enter passkey to continue
incorrect passkey
Precision medicine begins with understanding your genetic foundation. One sequencing event creates a lifelong platform for diagnosis, treatment, and prevention.
Explore the VisionA single sequencing event produces the most comprehensive diagnostic dataset in medicine. It does not expire, it does not need to be repeated, and it becomes more valuable with every advance in genomic science.
Traditional diagnostics are reactive: a symptom appears, a test is ordered, a narrow question is answered. Genomic sequencing inverts this model entirely. It produces a complete molecular portrait that can be reanalyzed as knowledge expands, as new conditions emerge, and as therapies evolve.
This is not incremental improvement. It is a foundational shift from episodic testing to a permanent diagnostic platform, one that eliminates the years-long odyssey that rare disease patients endure and replaces it with a single, definitive answer.
Sequenced once, reanalyzed indefinitely. Your genome becomes a living medical resource that grows in clinical utility over time.
Move from probabilistic screening to definitive molecular diagnosis across 20 characterized organ systems.
A single test that costs a fraction of the diagnostic workup it replaces, collapsing years of clinical uncertainty into one result.
Rare diseases are not rare in aggregate. The diagnostic tools exist. The evidence is published. What remains is implementation.
Genomic medicine is not abstract. It is a structured pipeline that transforms raw sequence data into precise, actionable clinical decisions.
Whole genome or exome sequencing captures your complete genetic blueprint in a single clinical encounter, creating a permanent diagnostic resource.
Expert analysis maps variants against clinical phenotype, published evidence, and population databases to deliver molecular-level diagnostic clarity.
A definitive diagnosis transforms the care plan: targeted therapies replace empiric treatments, unnecessary procedures are eliminated, and family members gain actionable risk insight.
Genomic sequencing has reached a cost-performance threshold that makes it not just viable but economically irrational to ignore. A test that costs $250 to $3,000 can prevent $50,000 to $500,000 or more in unnecessary downstream care over a patient's lifetime.
Genetic testing is not a cost center. It is the most efficient cost-elimination tool in the diagnostic arsenal.
The shift is already underway. Rapid genome sequencing in neonatal intensive care units has demonstrated measurable reductions in length of stay, management changes in the majority of diagnosed cases, and cost-effectiveness ratios that outperform most established medical interventions.
Fee-for-service sees genomic testing as an expense. Value-based models reveal it as the single most effective utilization management tool available, eliminating years of diagnostic waste with one intervention.
Unlike every other diagnostic in medicine, genomic data does not expire. The sequence performed today becomes more clinically valuable tomorrow as the knowledge base expands and new therapies emerge.
A single proband's diagnosis unlocks cascade testing across the entire family unit, multiplying the clinical return on a single sequencing investment and enabling prevention before disease manifests.